STTK
Shattuck Labs, Inc.
$5.49
-1.96%
2026-10-23
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Key Fundamentals
Forward P/E
-11.57
EPS (TTM)
$-0.44
ROE
-39.2%
Revenue Growth (YoY)
-66.6%
Profit Margin
0.0%
Debt/Equity
1.27
Price/Book
2.90
Beta
1.10
Market Cap
$609.2M
Avg Volume (10D)
1.7M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$8.15
60D Low
$5.19
Avg Volume
1.2M
Latest Close
$5.49
Get breakout alerts for STTK
Sign up for Breakout Scanner to receive daily notifications when STTK triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Shattuck Labs, Inc. (STTK) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors STTK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. STTK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.